Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 17,100 shares, adecreaseof32.7% from the July 15th total of 25,400 shares. Based on an average daily trading volume, of 30,100 shares, the days-to-cover ratio is currently 0.6 days. Currently,0.5% of the company’s shares are short sold. Currently,0.5% of the company’s shares are short sold. Based on an average daily trading volume, of 30,100 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pulmatrix stock. SBI Securities Co. Ltd. increased its position in shares of Pulmatrix, Inc. (NASDAQ:PULM) by 15.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 60,565 shares of the biotechnology company’s stock after purchasing an additional 8,208 shares during the period. SBI Securities Co. Ltd.’s holdings in Pulmatrix were worth $418,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 11.84% of the company’s stock.

Pulmatrix Stock Down 1.3%

PULM stock opened at $4.47 on Friday. The business has a 50 day moving average price of $6.13 and a two-hundred day moving average price of $6.78. The company has a market cap of $16.32 million, a price-to-earnings ratio of -2.06 and a beta of 1.45. Pulmatrix has a twelve month low of $1.78 and a twelve month high of $10.40.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($0.42) earnings per share for the quarter. Pulmatrix had a negative net margin of 122.46% and a negative return on equity of 97.25%.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen started coverage on Pulmatrix in a research report on Tuesday, May 20th. They set a “sell” rating on the stock.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.